Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474782 · ClinicalTrials.gov registry record
Analysis of Defocus Curve of Pre-Presbyopic and Emerging Presbyopic Patients
A clinical trial of Presbyopia, sponsored by Vance Thompson Vision.
- Completed
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT04474782: Completed study of Presbyopia, sponsored by Vance Thompson Vision.
NCT04474782 is a study of Presbyopia that has completed, run by Vance Thompson Vision. The registered enrollment target is 45 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474782, a study of Presbyopia, has completed, sponsored by Vance Thompson Vision.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Educating patients on visual performance with presbyopic correcting intraocular lenses is crucial. Understanding the defocus curve of pre-presbyopic and emerging presbyopic crystalline lens will provide eye care provides useful information to better educate patients on visual performance expectations after cataract surgery with a presbyopic correcting intraocular lens. Our objective will be to assess the subjective range of clear vision of a pre-presbyopic and emerging presbyopic patient population utilizing a defocus curve. A comparison of the pre-presbyopic and emerging presbyopic defocus curve to all FDA-approved presbyopic intraocular lenses will be discussed in the manuscript.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST There is not an intervention
Study Locations (1)
South Dakota
- Vance Thompson Vision - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2020-08-31 |
What the finished NCT04474782 record still lists
NCT04474782 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 1 intervention - of which There is not an intervention is the first listed.
NCT04474782 reports a single indexed study location in South Dakota.
Frequently Asked Questions
What is clinical trial NCT04474782 about?
NCT04474782 is a clinical study titled "Analysis of Defocus Curve of Pre-Presbyopic and Emerging Presbyopic Patients". Educating patients on visual performance with presbyopic correcting intraocular lenses is crucial. Understanding the defocus curve of pre-presbyopic and emerging presbyopic crystalline lens will provide eye care provides useful information to better educate patients on visual performance expectation...
What is the current status of trial NCT04474782?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2019-10-17. Estimated completion is 2020-08-31.
What conditions does trial NCT04474782 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT04474782?
The interventions under investigation include: There is not an intervention (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04474782?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474782 being conducted?
This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04474782's enrollment target sits among peer trials
45 30th of 38 higher than 9 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Comfort and Vision With TOTAL30 Multifocal Lenses
RECRUITING
-
North American Comfilcon A Clinical Study
RECRUITING
-
IC-8 Apthera IOL New Enrollment Post Approval Study
RECRUITING
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI